All In Biotech

Drug Trial Radar · NCT05050942

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

332

Actual

Start

Oct 22, 2021

Primary completion

Nov 2026

Study completion Nov 2028

Sponsor

Lead sponsor
Camurus ABIndustry
Sponsor type
Industry
First posted
Sep 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.

Conditions

  • Gastro-enteropancreatic Neuroendocrine Tumor

Interventions

  • CAM2029Drug

    CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection

  • Octreotide LARDrug

    Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection

  • Lanreotide ATGDrug

    Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)Time frame: From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months

Locations

86 sites in 12 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center (MCCC) - Phoenix

    Phoenix, Arizona

  • UCLA Ahmanson Biological Imaging Center

    Santa Monica, California

  • Rocky Mountain Cancer Centers - Denver - Midtown

    Denver, Colorado

  • Mayo Clinic Hospital - Florida

    Jacksonville, Florida

  • University of Kentucky (UK) - Markey Cancer Center

    Lexington, Kentucky

  • East Jefferson General Hospital

    Metairie, Louisiana

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Texas Oncology - Austin

    Austin, Texas

  • Texas Oncology - Dallas

    Dallas, Texas

  • The University of Texas - MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology - McAllen

    McAllen, Texas

  • Texas Oncology - San Antonio Northeast

    San Antonio, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • GenesisCare - North Shore

    Alexandria, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Hôpital Erasme

    Brussels, Belgium

  • Antwerp University Hospital

    Edegem, Belgium

  • Algemeen Ziekenhuis Maria Middelares

    Ghent, Belgium

  • AZ Nikolaas

    Sint-Niklaas, Belgium

  • London Health Sciences Centre

    London, Canada

  • Centre Hospitalier de l'Universite de Montreal - Notre-Dame Hospital

    Montreal, Canada

  • Jewish General Hospital

    Montreal, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Canada

  • Niagara Health System - St. Catharines General Site

    St. Catharines, Canada

  • Princess Margaret Cancer Centre

    Toronto, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Canada

  • BC Cancer Agency Vancouver Centre

    Vancouver, Canada

  • CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque

    Bordeaux, France

  • CHRU de Tours - Hopital Trousseau

    Chambray-lès-Tours, France

  • Centre Hospitalier Universitaire Dijon Bourgogne - L'Hopital General

    Dijon, France

  • Groupe Hospitalier de l'Institut Catholique de Lille - Hopital Saint Vincent de Paul

    Lille, France

  • CHU de Lyon - Groupement Hospitalier Edouard Herriot

    Lyon, France

  • CHU de Nantes - Hôtel-Dieu

    Nantes, France

  • Centre Eugène Marquis

    Rennes, France

  • Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre

    Strasbourg, France

  • Charite - UB - CVK - Medizinische Klinik

    Berlin, Germany

  • Universitaetsklinikum Erlangen - Hautklinik

    Erlangen, Germany

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.